2‐Chloro N6‐methyl‐(N)‐methanocarba‐2′‐deoxyadenosine‐3′,5′‐bisphosphate is a selective high affinity P2Y1 receptor antagonist
- 1 April 2002
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 135 (8) , 2004-2010
Abstract
We reported previously that bisphosphate derivatives of adenosine are antagonists of the P2Y1 receptor and that modification of the ribose in these analogues is tolerated in the P2Y1 receptor binding pharmacophore. Here we delineate the pharmacological activity of one such non‐nucleotide molecule, 2‐chloro N6‐methyl‐(N)‐methanocarba‐2′‐deoxyadenosine‐3′,5′‐bisphosphate (MRS2279), in which the ribose is replaced by a cyclopentane ring constrained in the (N)‐conformation by a cyclopropane moiety. MRS2279 antagonized 2MeSADP‐stimulated inositol phosphate formation in turkey erythrocyte membranes with competitive kinetics (pKB=7.75). High affinity competitive antagonism by MRS2279 was also observed at the human P2Y1 receptor (pKB=8.10) stably expressed in 1321N1 human astrocytoma cells. Antagonism was specific for the P2Y1 receptor since MRS2279 had no effect on activation of the human P2Y2, P2Y4, P2Y6, or P2Y11 receptors by their cognate agonists. MRS2279 also did not block the capacity of ADP to act through the Gi/adenylyl cyclase linked P2Y receptor of platelets to inhibit cyclic AMP accumulation. In contrast, the P2Y1 receptor is known to be obligatory in the process of ADP‐induced platelet aggregation, and MRS2279 competitively inhibited ADP‐promoted platelet aggregation with an apparent affnity (pKB=8.05) similar to that observed at the human P2Y1 receptor heterologously expressed in 1321N1 cells. Taken together these results illustrate selective high affinity antagonism of the P2Y1 receptor by a non‐nucleotide molecule that should prove useful for pharmacological delineation of this receptor in various tissues. British Journal of Pharmacology (2002) 135, 2004–2010; doi:10.1038/sj.bjp.0704673Keywords
This publication has 30 references indexed in Scilit:
- Activity of novel adenine nucleotide derivatives as agonists and antagonists at recombinant rat P2X receptorsDrug Development Research, 2000
- Acyclic Analogues of Deoxyadenosine 3‘,5‘-Bisphosphates as P2Y1 Receptor AntagonistsJournal of Medicinal Chemistry, 2000
- Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y1 receptor–null miceJournal of Clinical Investigation, 1999
- Competitive and selective antagonism of P2Y1 receptors by N6‐methyl 2′‐deoxyadenosine 3′,5′‐bisphosphateBritish Journal of Pharmacology, 1998
- P2Y1‐receptors in human platelets which are pharmacologically distinct from P2YADP‐receptorsBritish Journal of Pharmacology, 1998
- Deoxyadenosine Bisphosphate Derivatives as Potent Antagonists at P2Y1 ReceptorsJournal of Medicinal Chemistry, 1998
- The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cellsFEBS Letters, 1997
- Identification of potent P2Y‐purinoceptor agonists that are derivatives of adenosine 5′‐monophosphateBritish Journal of Pharmacology, 1996
- Potent agonist action of 2‐thioether derivatives of adenine nucleotides at adenylyl cyclase‐linked P2y‐purinoceptorsBritish Journal of Pharmacology, 1995
- P2-Purinergic Receptors: Subtype-Associated Signaling Responses and StructureAnnual Review of Pharmacology and Toxicology, 1995